GSK PLC Sponsored ADR

GSK Healthcare Drug Manufacturers General

GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.

Revenue
+3.75%
EPS
−14.7%
Free cash flow
+62.4%
Total debt
+33.2%

Quarter to September 2026, against a year earlier

50.31 0.10 −0.20%
Market cap
$101.0B
P/E
16.7×
Fwd P/E
14.6×
Dividend yield
3.60%
F-score
9/9
Altman Z
2.12
Beneish M
−2.46
Dividend safety
54/100
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
6 8 8 9

+8 more TTM periods

ROE
25.48% 30.74% 38.52% 39.92%
ROA
6.53% 8.01% 9.72% 9.63%
ROIC
9.61% 12.58% 15.14% 16.44%
Return on Tangible Assets
65.86% 89.82% 124.42% 105.05%
Average Days of Receivables
93.11 88.86 88.94 86.69
Free Cash Flow per Share
4.41 3.81 3.25 3.19
Free Cash Flow
8,830.02 7,647.98 6,540.67 6,455.04
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026